PE20121334A1 - Espiroindolinona-pirrolidinas con actividad sobre mdm2 - Google Patents
Espiroindolinona-pirrolidinas con actividad sobre mdm2Info
- Publication number
- PE20121334A1 PE20121334A1 PE2012000748A PE2012000748A PE20121334A1 PE 20121334 A1 PE20121334 A1 PE 20121334A1 PE 2012000748 A PE2012000748 A PE 2012000748A PE 2012000748 A PE2012000748 A PE 2012000748A PE 20121334 A1 PE20121334 A1 PE 20121334A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- pyrrolidine
- spiroindolinone
- fluor
- indol
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- -1 CYCLOBUTYL Chemical class 0.000 abstract 4
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical class [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229940095102 methyl benzoate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
REFERIDA A UN DERIVADO DE ESPIROINDOLINONA-PIRROLIDINA DE FORMULA (I), DONDE X E Y SON F, Cl, Br; R1 ES ALQUILO C1-C6 SELECCIONADO DE R9, R11 Y R10; R9 Y R10 SON METILO O FORMAN JUNTOS UN GRUPO CICLOPROPILO, CICLOBUTILO, CICLOPENTILO O CICLOHEXILO; R11 ES (CH2)q-R12; R12 ES H, OH, ALQUILO C1-C6, ALCOXI C1-C6, q ES 0, 1 O 2; R2 ES ARILO, HETEROARILO, ENTRE OTROS; R3, R4, R5, R6, R7 Y R8 SON H O F. SON COMPUESTOS PREFERIDOS: RAC-4-{[(2'S,3'R,4'S,5'R)-6-CLORO-4'-(3-CLORO-2-FLUOR-FENIL)-2'-(2,2-DIMETIL-PROPIL)-2-OXO-1,2-DIHIDRO-ESPIRO[INDOL-3,3'-PIRROLIDINA]-5'-CARBONIL]-AMINO}-BENZOATO DE METILO, (4-CARBAMOIL-FENIL)-AMIDA DEL ACIDO RAC-(2'S,3'R,4'S,5'R)-6-CLORO-4'-(3-CLORO-2-FLUOR-FENIL)-2'-(2,2-DIMETIL-PROPIL)-2-OXO-1,2-DIHIDRO-ESPIRO[INDOL-3,3'-PIRROLIDINA]-5'-CARBOXILICO QUIRAL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SOHN ANTAGONISTAS DE LAS INTERACCIONES MDM2 Y SON UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26579209P | 2009-12-02 | 2009-12-02 | |
| US38805410P | 2010-09-30 | 2010-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121334A1 true PE20121334A1 (es) | 2012-10-12 |
Family
ID=43608656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000748A PE20121334A1 (es) | 2009-12-02 | 2010-11-29 | Espiroindolinona-pirrolidinas con actividad sobre mdm2 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8088815B2 (es) |
| EP (1) | EP2507243B1 (es) |
| JP (1) | JP5647262B2 (es) |
| KR (1) | KR101418191B1 (es) |
| CN (1) | CN102741257B (es) |
| AR (1) | AR079226A1 (es) |
| AU (1) | AU2010326855B2 (es) |
| BR (1) | BR112012012872A2 (es) |
| CA (1) | CA2781823A1 (es) |
| CL (1) | CL2012001405A1 (es) |
| CO (1) | CO6541606A2 (es) |
| CR (1) | CR20120259A (es) |
| EC (1) | ECSP12011945A (es) |
| ES (1) | ES2543468T3 (es) |
| IL (1) | IL220010A (es) |
| MA (1) | MA33976B1 (es) |
| MX (1) | MX2012006260A (es) |
| MY (1) | MY160596A (es) |
| NZ (1) | NZ600024A (es) |
| PE (1) | PE20121334A1 (es) |
| PH (1) | PH12012501029A1 (es) |
| RU (1) | RU2571100C2 (es) |
| SG (1) | SG181465A1 (es) |
| TW (1) | TW201129571A (es) |
| WO (1) | WO2011067185A1 (es) |
| ZA (1) | ZA201204036B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2952522B1 (en) | 2007-01-31 | 2019-10-30 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| KR20120099462A (ko) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 ｍｄｍ2 길항제 |
| US20110118283A1 (en) * | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US8288431B2 (en) * | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| KR20170058446A (ko) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| US20120046306A1 (en) * | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| AU2011326395B2 (en) | 2010-11-12 | 2016-01-07 | Ascenta Licensing Corporation | Spiro-oxindole MDM2 antagonists |
| AU2012226890B2 (en) | 2011-03-10 | 2016-10-06 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
| US8629141B2 (en) | 2011-05-11 | 2014-01-14 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| AR088392A1 (es) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| CN103113854B (zh) * | 2013-02-06 | 2015-11-18 | 青岛奥环新能源科技发展有限公司 | 一种移动供热用复合相变材料及其制备方法 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| CN103342672B (zh) * | 2013-07-02 | 2015-12-23 | 扬州大学 | 取代吡咯烷-2-酮的新合成方法 |
| ES2712973T3 (es) | 2014-04-17 | 2019-05-17 | Univ Michigan Regents | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| JP6625638B2 (ja) * | 2014-08-18 | 2019-12-25 | ハドソン・バイオファーマ・インコーポレイテッド | Ｍｄｍ２阻害薬としてのスピロピロリジン |
| CA2956129C (en) | 2014-08-21 | 2022-10-25 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| RU2629750C2 (ru) * | 2015-04-09 | 2017-09-01 | Ян Андреевич Иваненков | НОВЫЕ ДИСПИРО-ИНДОЛИНОНЫ, ИНГИБИТОРЫ MDM2/p53 ВЗАИМОДЕЙСТВИЯ, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| PL3359542T3 (pl) | 2015-10-09 | 2021-09-20 | Boehringer Ingelheim International Gmbh | Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53 |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| CN105949221B (zh) * | 2016-05-11 | 2017-08-25 | 湖南科技大学 | 一种含螺吲哚‑2‑酮衍生物及其制备方法和作为抗癌药物的应用 |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| EP3498712B1 (en) * | 2016-08-08 | 2024-01-03 | Jiangsu Yayo Biotechnology Co. Ltd | Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof |
| EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
| RU2730287C1 (ru) * | 2019-08-30 | 2020-08-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Новые 2',5'-диарилспиро[индол-3,3'-пирролидин]-2(1н)-оны и способ их получения |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CA3181715A1 (en) | 2020-08-27 | 2022-03-03 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| US12569564B2 (en) | 2021-01-23 | 2026-03-10 | Newave Pharmaceutical Inc. | Spirocyclic MDM2 modulator and uses thereof |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN115215872A (zh) * | 2021-04-15 | 2022-10-21 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物 |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| CN113387957B (zh) * | 2021-06-09 | 2022-08-09 | 江苏亚尧生物科技有限公司 | 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途 |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US11919910B2 (en) * | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| CN116283701B (zh) * | 2021-12-21 | 2025-04-22 | 中国科学院上海药物研究所 | 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物 |
| CN114773327B (zh) * | 2022-04-18 | 2023-08-18 | 广东优康精细化工有限公司 | 一种吡噻菌胺中间体的制备方法 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2759935A (en) * | 1953-02-18 | 1956-08-21 | Bristol Lab Inc | Substituted 3-phenyloxindoles |
| US3441570A (en) * | 1966-01-20 | 1969-04-29 | Parke Davis & Co | 3-tertiary aminoalkylamino-3-phenyl oxindole compounds |
| US3686210A (en) * | 1970-01-13 | 1972-08-22 | American Home Prod | 2-acylamido-3-aryl-3h-indol-3-ol esters and related compounds |
| US4020179A (en) * | 1975-05-15 | 1977-04-26 | Richardson-Merrell Inc. | 7-Substituted-2-indolinones |
| JPS55129284A (en) | 1979-03-27 | 1980-10-06 | Shionogi & Co Ltd | 3-(1-imipazolyl)indolin-2-one |
| DE3714473A1 (de) | 1987-04-30 | 1988-11-10 | Basf Ag | Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose |
| RU2084449C1 (ru) * | 1994-03-02 | 1997-07-20 | Всероссийский научный центр по безопасности биологически активных веществ | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью |
| FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
| WO1998054167A1 (en) | 1997-05-28 | 1998-12-03 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Indole compounds |
| US6511974B1 (en) * | 1997-07-30 | 2003-01-28 | Wyeth | Tricyclic vasopressin agonists |
| EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
| JP2000191661A (ja) | 1998-12-25 | 2000-07-11 | Mitsubishi-Tokyo Pharmaceuticals Inc | 環状アミド化合物 |
| DE60026297T2 (de) | 1999-05-21 | 2006-11-02 | Bristol-Myers Squibb Co. | Pyrrolotriazin kinasehemmer |
| NZ516452A (en) * | 1999-07-21 | 2004-06-25 | Astrazeneca Ab | Spirooxindole Derivatives |
| FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| AU2003230581A1 (en) | 2002-03-15 | 2003-09-29 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| DE202004014849U1 (de) * | 2004-09-23 | 2005-02-03 | Trw Automotive Safety Systems Gmbh | Vorrichtung zur Bestimmung eines absoluten Drehwinkels |
| WO2006080574A1 (ja) | 2005-01-28 | 2006-08-03 | Taisho Pharmaceutical Co., Ltd. | １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物 |
| KR100944301B1 (ko) | 2005-02-22 | 2010-02-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｍｄｍ２의 소분자 억제제 및 이의 용도 |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| CA2644758A1 (en) | 2006-03-13 | 2007-09-20 | F. Hoffmann-La Roche Ag | Spiroindolinone derivatives |
| US7495007B2 (en) * | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| US7737174B2 (en) * | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| SG174107A1 (en) | 2006-08-30 | 2011-09-29 | Univ Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2008080822A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Epimerization methodologies for recovering stereo isomers in high yield and purity |
| US7553833B2 (en) * | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| AU2009294673B2 (en) * | 2008-09-18 | 2014-08-14 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| KR20120099462A (ko) * | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 ｍｄｍ2 길항제 |
| SG184288A1 (en) * | 2010-04-09 | 2012-11-29 | Univ Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
-
2010
- 2010-11-04 US US12/939,234 patent/US8088815B2/en not_active Expired - Fee Related
- 2010-11-29 WO PCT/EP2010/068353 patent/WO2011067185A1/en not_active Ceased
- 2010-11-29 CN CN201080062931.4A patent/CN102741257B/zh not_active Expired - Fee Related
- 2010-11-29 RU RU2012125763/04A patent/RU2571100C2/ru not_active IP Right Cessation
- 2010-11-29 JP JP2012541424A patent/JP5647262B2/ja not_active Expired - Fee Related
- 2010-11-29 NZ NZ600024A patent/NZ600024A/en not_active IP Right Cessation
- 2010-11-29 MA MA34939A patent/MA33976B1/fr unknown
- 2010-11-29 PH PH1/2012/501029A patent/PH12012501029A1/en unknown
- 2010-11-29 MY MYPI2012002434A patent/MY160596A/en unknown
- 2010-11-29 TW TW099141297A patent/TW201129571A/zh unknown
- 2010-11-29 KR KR1020127016926A patent/KR101418191B1/ko not_active Expired - Fee Related
- 2010-11-29 ES ES10793189.1T patent/ES2543468T3/es active Active
- 2010-11-29 MX MX2012006260A patent/MX2012006260A/es active IP Right Grant
- 2010-11-29 BR BR112012012872A patent/BR112012012872A2/pt not_active Application Discontinuation
- 2010-11-29 CA CA2781823A patent/CA2781823A1/en not_active Abandoned
- 2010-11-29 EP EP10793189.1A patent/EP2507243B1/en not_active Not-in-force
- 2010-11-29 PE PE2012000748A patent/PE20121334A1/es not_active Application Discontinuation
- 2010-11-29 AU AU2010326855A patent/AU2010326855B2/en not_active Ceased
- 2010-11-29 SG SG2012040341A patent/SG181465A1/en unknown
- 2010-11-30 AR ARP100104410A patent/AR079226A1/es unknown
-
2012
- 2012-05-18 CR CR20120259A patent/CR20120259A/es unknown
- 2012-05-24 IL IL220010A patent/IL220010A/en not_active IP Right Cessation
- 2012-05-24 CO CO12086101A patent/CO6541606A2/es not_active Application Discontinuation
- 2012-05-30 CL CL2012001405A patent/CL2012001405A1/es unknown
- 2012-06-01 EC ECSP12011945 patent/ECSP12011945A/es unknown
- 2012-06-01 ZA ZA2012/04036A patent/ZA201204036B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121334A1 (es) | Espiroindolinona-pirrolidinas con actividad sobre mdm2 | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| PE20120126A1 (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
| PE20091315A1 (es) | Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
| PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| PE20142452A1 (es) | AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2 | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PE20121180A1 (es) | (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20130651A1 (es) | Derivados de imidazopiridina y su procedimiento de preparacion | |
| AR094312A1 (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
| PE20110296A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de orexina | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR086318A1 (es) | Piridil aminopiridinas como inhibidores de syk | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |